101 related articles for article (PubMed ID: 7557620)
1. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody.
Deshane J; Cabrera G; Grim JE; Siegal GP; Pike J; Alvarez RD; Curiel DT
Gynecol Oncol; 1995 Oct; 59(1):8-14. PubMed ID: 7557620
[TBL] [Abstract][Full Text] [Related]
2. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines.
Deshane J; Loechel F; Conry RM; Siegal GP; King CR; Curiel DT
Gene Ther; 1994 Sep; 1(5):332-7. PubMed ID: 7584099
[TBL] [Abstract][Full Text] [Related]
3. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.
Wright M; Grim J; Deshane J; Kim M; Strong TV; Siegal GP; Curiel DT
Gene Ther; 1997 Apr; 4(4):317-22. PubMed ID: 9176517
[TBL] [Abstract][Full Text] [Related]
4. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy.
Deshane J; Siegal GP; Wang M; Wright M; Bucy RP; Alvarez RD; Curiel DT
Gynecol Oncol; 1997 Mar; 64(3):378-85. PubMed ID: 9062138
[TBL] [Abstract][Full Text] [Related]
5. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
6. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis.
Deshane J; Grim J; Loechel S; Siegal GP; Alvarez RD; Curiel DT
Cancer Gene Ther; 1996; 3(2):89-98. PubMed ID: 8729907
[TBL] [Abstract][Full Text] [Related]
7. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.
Alvarez RD; Barnes MN; Gomez-Navarro J; Wang M; Strong TV; Arafat W; Arani RB; Johnson MR; Roberts BL; Siegal GP; Curiel DT
Clin Cancer Res; 2000 Aug; 6(8):3081-7. PubMed ID: 10955787
[TBL] [Abstract][Full Text] [Related]
8. erbB-2 knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells.
Grim J; Deshane J; Feng M; Lieber A; Kay M; Curiel DT
Am J Respir Cell Mol Biol; 1996 Sep; 15(3):348-54. PubMed ID: 8810638
[TBL] [Abstract][Full Text] [Related]
9. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
10. Targeted tumor killing via an intracellular antibody against erbB-2.
Deshane J; Siegal GP; Alvarez RD; Wang MH; Feng M; Cabrera G; Liu T; Kay M; Curiel DT
J Clin Invest; 1995 Dec; 96(6):2980-9. PubMed ID: 8675670
[TBL] [Abstract][Full Text] [Related]
11. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
[TBL] [Abstract][Full Text] [Related]
12. [Anti-tumor effect of lentivirus-mediated MUCI antibody-targeted gene therapy with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice].
Kong B; Wang W; Liu C; Ma D; Qu X; Jiang J; Yang X; Zhang Y; Jiang S
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(17):1207-10. PubMed ID: 12475412
[TBL] [Abstract][Full Text] [Related]
13. Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo.
Stackhouse MA; Buchsbaum DJ; Grizzle WE; Bright SJ; Olsen CC; Kancharla S; Mayo MS; Curiel DT
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):817-22. PubMed ID: 9845103
[TBL] [Abstract][Full Text] [Related]
14. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
Li D; Williams JI; Pietras RJ
Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
[TBL] [Abstract][Full Text] [Related]
15. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
16. Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells.
Warrenfeltz SW; Lott SA; Palmer TM; Gray JC; Puett D
Mol Cancer Res; 2008 Nov; 6(11):1775-85. PubMed ID: 19010824
[TBL] [Abstract][Full Text] [Related]
17. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
18. Ectopic expression of pRb2/p130 suppresses the tumorigenicity of the c-erbB-2-overexpressing SKOV3 tumor cell line.
Pupa SM; Howard CM; Invernizzi AM; De Vecchi R; Giani C; Claudio PP; Colnaghi MI; Giordano A; Ménard S
Oncogene; 1999 Jan; 18(3):651-6. PubMed ID: 9989815
[TBL] [Abstract][Full Text] [Related]
19. [Immuno-therapeutic study of anti-idiotype minibody (single chain Fv-CH3) on ovarian carcinoma bearing mice].
Li Y; Chang XH; Cui H; Yang WL; Feng J; Wei LH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Aug; 25(4):451-6. PubMed ID: 12974094
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma.
Mahasreshti PJ; Navarro JG; Kataram M; Wang MH; Carey D; Siegal GP; Barnes MN; Nettelbeck DM; Alvarez RD; Hemminki A; Curiel DT
Clin Cancer Res; 2001 Jul; 7(7):2057-66. PubMed ID: 11448924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
